摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[2-(4-溴苯氧基)乙基]-1H-咪唑 | 250600-43-2

中文名称
1-[2-(4-溴苯氧基)乙基]-1H-咪唑
中文别名
——
英文名称
1-(2-(4-bromophenoxy)ethyl)-1H-imidazole
英文别名
1-[2-(4-Bromophenoxy)ethyl]-1H-imidazole;1-[2-(4-Bromophenoxy)ethyl]imidazole
1-[2-(4-溴苯氧基)乙基]-1H-咪唑化学式
CAS
250600-43-2
化学式
C11H11BrN2O
mdl
MFCD01308498
分子量
267.125
InChiKey
ZVSKOSCGJSFYKY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    426.7±25.0 °C(Predicted)
  • 密度:
    1.42±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    15
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.181
  • 拓扑面积:
    27
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933290090

SDS

SDS:aa38991d38dfaf12c8dcf4b95ea1d69e
查看

反应信息

  • 作为反应物:
    参考文献:
    名称:
    钯介导的使用芳基卤化物和氰胺的11 C-碳羰基化
    摘要:
    描述了使用钯介导的氨基羰基化与11 C-CO,芳基卤化物和氰胺进行的11 C-N-氰基苯甲酰胺的稳健而高产的放射化学合成。半制备型HPLC后,双齿配体1,1'-双(二苯基膦基)二茂铁从芳基碘化物,溴化物,三氟甲磺酸盐,甚至氯化物中提供了11种C-N-氰基苯甲酰胺,放射化学产率为28-79%。为了进一步突出该方法的实用性,以34-71%的放射化学收率合成了新型的氟苯甲酸,黑麦草酸,达唑昔本和他米巴罗汀的11 C-N-氰基苯甲酰胺类似物。
    DOI:
    10.1039/c7ob01064h
  • 作为产物:
    描述:
    咪唑1-(2-溴氧基)-4-溴苯 在 sodium hydride 作用下, 以 四氢呋喃 为溶剂, 以65%的产率得到1-[2-(4-溴苯氧基)乙基]-1H-咪唑
    参考文献:
    名称:
    1-[(Aryloxy)alkyl]-1<I>H</I>-imidazoles as Inhibitors of Neuronal Nitric Oxide Synthase
    摘要:
    DOI:
    10.1211/146080899128735225
点击查看最新优质反应信息

文献信息

  • [EN] COMPOSITIONS AND METHODS FOR INHIBITING BMP<br/>[FR] COMPOSITIONS ET PROCÉDÉS D'INHIBITION DE LA BMP
    申请人:BRIGHAM & WOMENS HOSPITAL
    公开号:WO2016011019A1
    公开(公告)日:2016-01-21
    The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
    本发明提供了BMP信号通路的小分子抑制剂,以及用于抑制BMP信号通路的组合物和方法。这些化合物和组合物可用于调节细胞生长、分化、增殖和凋亡,因此可用于治疗与BMP信号通路相关的疾病或症状,包括炎症、心血管疾病、血液疾病、癌症和骨骼疾病,以及用于调节细胞分化和/或增殖。这些化合物和组合物还可用于降低ApoB-100或LDL的循环水平,并治疗或预防获得性或先天性高胆固醇血症或高脂蛋白血症;与脂质吸收或代谢缺陷相关的疾病、紊乱或综合征;或由高脂血症引起的疾病、紊乱或综合征。
  • NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
    申请人:ROTH Gerald Juergen
    公开号:US20120157425A1
    公开(公告)日:2012-06-21
    The invention relates to new piperidine derivatives of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    该发明涉及新的哌啶衍生物,其化学式I,用作药物,用于治疗的方法以及含有它们的药物组合物。
  • Compositions and Methods for Inhibiting BMP
    申请人:LEE Arthur
    公开号:US20170197968A1
    公开(公告)日:2017-07-13
    The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
  • US5708171A
    申请人:——
    公开号:US5708171A
    公开(公告)日:1998-01-13
  • US9006450B2
    申请人:——
    公开号:US9006450B2
    公开(公告)日:2015-04-14
查看更多